Ibrutinib-associated focal segmental glomerulosclerosis and the impact of podocin mutations in chronic lymphocytic leukemia
February 2024 | New Publication
Czogalla J et al., Kidney Int. 2024
Here, they report a case of FSGS linked to IBRU treatment in a 57-year-old male patient with CLL and provide insight into the underlying mechanism.
For further information visit:
KI - Ibrutinib-associated focal segmental glomerulosclerosis and the impact of podocin mutations in chronic lymphocytic leukemia
More articles in this category
Martinistraße 52
Campus Research N27
20246 Hamburg Germany
